Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Business Wire
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On May 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company’s common stock with an exercise price of $22.64, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options are exercisable for an aggregate of 72,769 shares of the Company’s common stock. Each of the four options was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The options each vest as to 25% on May 1, 2025, and then in three equal installments thereafter such that the option will be fully vested on May 1, 2028. The options each ha
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewswire
- What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.MarketBeat
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
- Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 5/10/24 - Form SC
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- RNAC's page on the SEC website